Poster Session D
8:30 – 10:30 a.m. ET Tuesday, Nov. 9
All ACR Convergence 2021 poster presentations are available on demand to registered meeting participants through March 11, 2022.
What is your poster about?
We evaluated the course and severity of SARS-CoV-2 infection in patients with rheumatic diseases receiving biological therapies. We observed that the infection was better and less severe with tumor necrosis factor inhibitors and worse and more severe with rituximab (higher percentage of pneumonia development, hospital admission, and greater severity), with no development of SARS-CoV-2 IgG antibody.
Why did you decide to investigate this topic?
We wanted to demonstrate the belief we had in clinical practice that different biological therapies influence the evolution of the SARS-CoV-2 infection differently.
What are you working on next related to this research?
We are evaluating the response to vaccination against SARS-CoV-2 in our rheumatic patients, given the possible different response that they may have when different biological therapies are received.
What excites you most about your work?
Considering the persistent severity of the COVID-19 pandemic, these results may influence the decision to initiate one biological therapy or another in rheumatic patients.
REGISTER TODAY FOR ACR CONVERGENCE
If you haven’t registered for ACR Convergence 2021, register today to access all of the valuable content during the meeting, November 3–10. Registration also includes on-demand access to the virtual platform (session recordings, Poster Hall, Community Hubs, and ShowRheum) until March 11, 2022.